Introduction
Materials and methods
Trials
Drug, dose, number randomised | |||||||||
---|---|---|---|---|---|---|---|---|---|
Study | Details of participants | Relevant medical history | Celecoxib | Placebo | Other | Duration (weeks) | Efficacy outcomes | Safety outcomes | Total in trial (ITT) |
Osteoarthritis
| |||||||||
C-002 | OA Hip/Knee (ACR) requiring daily NSAID therapy, FCC 1–3 Stable hypertension, type 2 diabetes Age 62 (range 40–89) years 61% female ≥ 75% Caucasian | Data not provided | 1 × 200 mg/day, n = 36 | No placebo | Rofecoxib 1 × 25 mg/day, n = 132 Naproxen 2 × 500 mg/day, n = 128 | 12 | WOMAC Patient's assessment of arthritis pain VAS Patient's global assessment of arthritis Patient's satisfaction Withdrawal due to lack of efficacy | Withdrawals Adverse events Serious adverse events Laboratory tests | 396 |
C-003 | OA Knee (ACR) with flare, requiring daily NSAID/analgesic, FCC 1–3, baseline pain 40 on 100 mm VAS. Age 63 (range 39–90) years Duration of disease 8 (range 0.2–51) years 67% female ≥ 85% Caucasian | Cardioprotective ASA 20% NSAID intolerance 4% GI ulcer 6% GI bleed 1% Renal insufficiency 1% | 1 × 200 mg/day, n = 189 | n = 96 | Rofecoxib 1 × 25 mg/day, n = 190 | 6 | Patient's assessment of arthritis pain WOMAC (total) Patient's global assessment of arthritis pain VAS OASI Physician's global assessment of arthritis Patient's assessment of satisfaction | Withdrawals Adverse events Serious adverse events Laboratory tests | 475 |
C-010 | OA Hip/Knee (K-L 2–4), requiring chronic NSAID/analgesic, initial pain 40–90 on 100 mm VAS Age 63 (range 38–91) years Duration of disease 9 (0.1–54) years 62% female | Cardioprotective ASA 20% GI-related NSAID intolerance 1% Gastroduodenal ulcer 8% GI bleed 0.6% Some type of GI history (unspecified) 48% | 1 × 200 mg/day n = 181 | n = 172 | Paracetamol 4 × 1,000 mg/day, n = 171 | 6 | WOMAC index MDHAQ Patient's global rating of helpfulness Physician's global assessment of status SF-36 General clinical safety | Withdrawals Adverse events Serious adverse events Laboratory tests | 524 |
C-013 | OA Knee (ACR) with flare, FCC 1–3 Mean age 62 (range 29–92) years Duration of disease 10 (0.2–50) years 69% female 90% Caucasian | Cardioprotective ASA permitted NSAID intolerance 13% Gastroduodenal ulcer 16% GI bleed 3% CVD 52% | 2 × 40 mg/day, n = 73 2 × 100 mg/day, n = 75 2 × 200 mg/day, n = 73 | n = 70 | No active comparator | 2 | Physican's global assessment Patient's global assessment Patient's arthritis pain SF-36 | Withdrawals Adverse events Serious adverse events Laboratory tests | 291 |
C-020 | OA knee/hip (ACR) with flare, FCC 1–3 Age 62 (range 21–89) years Duration of disease 9 (0.1–52) years 66% female 79% Caucasian | Cardioprotective ASA permitted NSAID intolerance 7% Gastroduodenal ulcer 9% GI bleed 2% CVD 53% | 2 × 50 mg/day, n = 218 2 × 100 mg/day, n = 217 2 × 200 mg/day, n = 222 | n = 219 | Naproxen 2 × 500 mg/day, n = 216 | 12 | Patient's global assessment Physician's global assessment WOMAC Patient's assessment of pain | Withdrawals Adverse events Serious adverse events Laboratory tests | 1,092 |
C-021 | OA Knee/Hip (ACR) with flare, FCC 1–3 No ulcer at baseline endoscopy Age 61 (range 22–89) years Duration of disease 9 (range 0.1–52) years 54% female 83% Caucasian | Cardioprotective ASA permitted. NSAID intolerance 10% Gastroduodenal ulcer 17% GI bleed 2% CVD 60% | 2 × 50 mg/day, n = 258 2 × 100 mg/day, n = 239 2 × 200 mg/day, n = 237 | n = 247 | Naproxen 2 × 500 mg/day, n = 233 | 12 | Patient's global assessment Patient's assessment of pain Physician's global assessment WOMAC | Withdrawals Adverse events Serious adverse events Laboratory tests Endoscopic ulcers | 1,214 |
C-042 | Symptomatic OA Hip/Knee (ACR) ≥ 6 months, requiring NSAID, FCC 1–3 Age 63 (range 34–91) years Duration of disease 7 (0.5–48) years 72% female 94% Caucasian | NSAID intolerance 2% Gastroduodenal ulcer 3% GI bleed 0.5% CVD 45% | 2 × 100 mg/day, n = 346 | No placebo | Diclofenac 2 × 50 mg/day, n = 341 | 6 | Patient's global assessment Patient's assessment of pain Physician's global assessment SF-36 | Withdrawals Adverse events Serious adverse events Laboratory tests | 667 |
C-047 | OA Knee (ACR) with flare, FCC 1–3 Age 63 (29–91) years Duration of disease 9 (0.5–60) years 72% female 84% Caucasian | Cardioprotective ASA permitted NSAID intolerance 10% Gastroduodenal ulcer 10% GI bleed 4% CVD 62% | 2 × 25 mg/day, n = 100 2 × 100 mg/day, n = 101 2 × 400 mg/day, n = 99 | n = 101 | No active comparator | 4 | Patient's global assessment Patient's assessment of pain Physician's global assessment SF-36 WOMAC | Withdrawals Adverse events Serious adverse events Laboratory tests | 401 |
C-054 | OA Hip (ACR) with flare, FCC 1–3 Age 62 (28–93) years Duration of disease 7 (0.1–64) years 66% female 92% Caucasian | Cardioprotective ASA permitted NSAID intolerance 13% Gastroduodenal ulcer 12% GI bleed 2% CVD 60% | 2 × 50 mg/day, n = 216 2 × 100 mg/day, n = 207 2 × 200 mg/day, n = 213 | n = 217 | Naproxen 2 × 500 mg/day, n = 207 | 12 | Patient's global assessment Patient's assessment of pain Physician's global assessment SF-36 WOMAC | Withdrawals Adverse events Serious adverse events Laboratory tests | 1,060 |
C-060 | OA Knee (ACR) with flare, FCC 1–3 Age 63 (29–88) years Duration of disease 9 (0.1–59) years 66% female 88% Caucasian | Cardioprotective ASA permitted NSAID intolerance 4% Gastroduodenal ulcer 6% GI bleed 2% CVD 58% | 2 × 100 mg/day, n = 231 1 × 200 mg/day, n = 222 | n = 231 | No active comparator | 6 | Patient's global assessment Patient's assessment of pain Physician's global assessment SF-36 WOMAC | Withdrawals Adverse events Serious adverse events Laboratory tests | 684 |
C-087 | OA Knee (ACR) with flare, FCC 1–3 Age 61 (18–89) years Duration of disease 9 (0.1–60) years 70% female 86% Caucasian | Cardioprotective ASA permitted NSAID intolerance 7% Gastroduodenal ulcer 16% GI bleed 2% CVD 64% | 2 × 100 mg/day, n = 241 1 × 200 mg/day, n = 231 | n = 243 | No active comparator | 6 | Patient's global assessment Patient's assessment of pain Physician's global assessmen WOMAC | Withdrawals Adverse events Serious adverse events Laboratory tests | 715 |
C-096 | OA Knee/Hip/Hand ≥ 6 months (ACR) requiring daily analgesic/ NSAID, FCC 1–3 Age 62 (range 21–96) years 76% female Duration of disease 7 (0.3–59) years | Cardioprotective ASA use 7% CVD 41% Renal insufficiency 0.2% Respiratory disease 5% Diabetes 8% | 2 × 100 mg/day, n = 4,393 2 × 200 mg/day, n = 4,407 | No placebo | Naproxen 2 × 500 mg/day, n = 905 Diclofenac 2 × 50 mg/day, n = 3,489 | 12 | Patient's global rating of arthritis Patient's assessment of pain (VAS) WOMAC Physician's global assessment of arthritis | Withdrawals Adverse events Serious adverse events Laboratory tests | 13,194 |
C-118 | OA Knee (ACR) with flare, FCC 1–3 Age 61 (29–88) years Duration of disease 8 (0.1–62) years 65% female 82% Caucasian | Cardioprotective ASA permitted NSAID intolerance 3% Gastroduodenal ulcer 8% GI bleed 1% CVD 66% | 2 × 100 mg/day, n = 199 | n = 200 | Diclofenac 3 × 50 mg/day, n = 199 | 6 | Patient's global assessment Patient's assessment of pain Physician's global assessment WOMAC | Withdrawals Adverse events Serious adverse events Laboratory tests | 598 |
C-149 | OA Hip/Knee/Hand (ACR) requiring NSAID, FCC 1–3 Stable treated hypertension Age 74 (range 64–95) years Duration of disease range 0.3–61 years 67% female Majority Caucasian | Cardioprotective ASA 38% NSAID intolerance 3% Gastroduodenal ulcer 10% GI bleed 3% Oedema 26% CHF 5% | 1 × 200 mg/day, n = 411 | No placebo | Rofecoxib 25 mg/day, n = 399 | 6 | Oedema Aggravated hypertension Renal events | Withdrawals Adverse events Serious adverse events Laboratory tests | 810 |
C-152 | OA Knee (ACR) with flare, FCC 1–3, baseline pain 35 on 100 mm VAS Age 62 (range 40–88) years Duration of disease 11 (range 0.5–s47) years 71% female 80% Caucasian | Cardioprotective ASA permitted NSAID intolerance 4% Gastroduodenal ulcer 9% GI bleed 0.5% | 1 × 200 mg/day, n = 63 | n = 60 | Rofecoxib 1 × 25 mg/day, n = 59 | 6 | Patient's assessment of arthritis pain OA VAS scale Patient's global assessment of arthritis WOMAC | Withdrawals Adverse events Serious adverse events Laboratory tests | 182 |
C-181 | OA Hip/Knee/Hand (ACR) requiring daily NSAID, FCC 1–3 Stable treated hypertension Age 73 (range 65–96) years Duration of disease 12 (0–63) years 62% female 88% Caucasian | Cardioprotective ASA permitted NSAID intolerance 2% Gastroduodenal ulcer 8% GI bleed 2% Oedema 27% CHF 3% | 1 × 200 mg/day, n = 549 | No placebo | Rofecoxib 1 × 25 mg/day, n = 543 | 6 | Blood pressure Oedema Weight Anti-hypertensive medication | Withdrawals Adverse events Serious adverse events Laboratory tests | 1,092 |
C-209 | OA Knee with flare (ACR), requiring chronic NSAID, FCC 1–3, initial pain 40–90 on 100 mm VAS Age 58 (range 45–83) years Duration of disease 5 (range 0.1–36) years 80% female Afro-American population | Data not provided | 1 × 200 mg/day, n = 125 | n = 66 | Naproxen 2 × 500 mg/day, n = 125 | 6 | Patient's assessment of arthritis pain Patient's global assessment Physician's global assessment WOMAC | Withdrawals Adverse events Serious adverse events Laboratory tests | 316 |
C-210 | OA Knee (ACR) with flare, FCC 1–3, requiring daily therapy, baseline pain 40–90 on 100 mm VAS Age 65 (range 42–90) years 68% female Duration of disease 5 (0.3–38) years Asian American population 100% Asian descent | Data not provided | 1 × 200 mg/day, n = 145 | n = 76 | Naproxen 2 × 500 mg/day, n = 141 | 6 | Patient's assessment of arthritis pain Patient's global assessment Physician's global assessment Pain Satisfaction WOMAC | Withdrawals Adverse events Serious adverse events Laboratory tests | 362 |
C-211 | OA Knee (ACR) with flare, requiring daily NSAID, FCC 1–3, baseline pain 40–90 on 100 mm VAS Age 60 (range 40–88) years Duration of disease 6 (range 0.1–36 yrs) years 67% female Hispanic population | Data not provided | 1 × 200 mg/day, n = 125 | n = 61 | Naproxen 2 × 500 mg/day, n = 129 | 6 | Patient's assessment of arthritis pain Patient's global assessment Physician's global assessment WOMAC Patient's satisfaction | Withdrawals Adverse events Serious adverse events Laboratory tests | 315 |
C-216 | OA Knee, symptomatic, requiring NSAID, initial pain 40 on 100 mm VAS Age 63 (range 20–92) years Duration of disease 4 (range 0.1–37) years 66% female Asian population | Cardioprotective ASA 3% NSAID intolerance 0.1% GI bleed 0.2% Gastroduodenal ulcer 6% CVD 30% | 2 × 100 mg/day, n = 382 | n = 192 | Loxoprofen 3 × 60 mg/day, n = 385 | 4 | Final global improvement rating Patient's assessment of arthritis pain Physician's and patient's global assessment of arthritis WOMAC | Withdrawals Adverse events Serious adverse events Laboratory tests Global safety rating | 959 |
C-249 | OA Hip/Knee (K-L confirmed), baseline pain 40–90 on 100 mm VAS Age 63 (range 45–89) years Duration of disease 9 (range 0.1–50) years 66% female ≥ 80% Caucasian | Cardioprotective ASA 21% GI-related NSAID intolerance 2% Gastroduodenal ulcer 7% GI bleed 0.7% | 1 × 200 mg/day, n = 189 | n = 182 | Paracetamol 4 × 1,000 mg/day, n = 185 | 2 × 6 crossover | WOMAC MDHAQ Investigator global assessment Patient's assessments of helpfulness and arthritis SF-36 | Withdrawals Adverse events Serious adverse events Laboratory tests | 556 |
Rheumatoid arthritis
| |||||||||
C-012 | Adult RA with flare (ACR) ≥ 6 months, requiring NSAID, FCC 1–3 Age 56 (range 21–86) years Duration of disease 11 (range 0.5–50) years 78% female 84% Caucasian | Cardioprotective ASA permitted NSAID intolerance 9% Gastroduodenal ulcer 3% GI bleed 0.6% CVD 43% | 2 × 40 mg/day, n = 80 2 × 200 mg/day, n = 82 2 × 400 mg/day, n = 81 | n = 84 | No active comparator | 4 | Patient's global rating of arthritis Arthritis pain, joint tenderness, joint swelling | Withdrawals Adverse events Serious adverse events Laboratory tests | 327 |
C-022 | RA with flare (ACR) requiring NSAID, FCC 1–3 No ulcer at baseline endoscopy Age 54 (range 20–90) years Duration of disease 10 (0.3–58) years 73% female 86% Caucasian | Cardioprotective ASA permitted NSAID intolerance 10% Gastroduodenal ulcer 15% GI bleed 2% CVD 44% | 2 × 100 mg/day, n = 240 2 × 200 mg/day, n = 235 2 × 400 mg/day, n = 217 | n = 231 | Naproxen 2 × 500 mg/day, n = 225 | 12 | Patient's global assessment of arthritis Physician's global assessment of arthritic condition No. of swollen joints ACR-20 responder index No. of tender/painful joints | Withdrawals Adverse events Serious adverse events Laboratory tests Endoscopic ulcers | 1,148 |
C-023 | RA (ACR) with flare requiring NSAID, FCC 1–3 Age 55 (range 21–84) years Duration of disease 10 (range 0.3–60) years 73% female 86% Caucasian | Cardioprotective ASA permitted NSAID intolerance 10% Gastroduodenal ulcer 8% GI bleed 1% CVD 44% | 2 × 100 mg/day, n = 228 2 × 200 mg/day, n = 218 2 × 400 mg/day, n = 217 | n = 221 | Naproxen 2 × 500 mg/day, n = 218 | 12 | Patient's global assessment of arthritis Physician's global assessment of arthritic condition No. of swollen joints ACR -20 responder index No. of tender/painful joints | Withdrawals Adverse events Serious adverse events Laboratory tests | 1,102 |
C-041 | Adult onset RA (ACR) ≥ 6 months, requiring NSAID, FCC 1–3 No ulcer at baseline endoscopy Age 55 (range 20–85) years Duration of disease10 (0.6–53) years 73% female 98% Caucasian | Cardioprotective ASA not permitted NSAID intolerance 7% Gastroduodenal ulcer 8% GI bleed 0.7% CVD 25% | 2 × 200 mg/day, n = 326 | No placebo | Diclofenac (slow release) 2 × 75 mg/day, n = 329 | 24 | Patient's global assessment Physician's global assessment Swollen joints Patient's assessment of arthritis pain SF-36 | Withdrawals Adverse events Serious adverse events Laboratory tests Endoscopic ulcers (not all patients had endoscopy) | 655 |
Osteoarthritis and rheumatoid arthritis
| |||||||||
C-062 | OA/RA ≥ 3 months, requiring NSAID, FCC 1–3 No ulcer at baseline endoscopy Duration of OA 10 (0.3–50) years, RA 10 (0.4–43) years Age 57 (range 22–86) years 67% female 83% Caucasian | Cardioprotective ASA permitted NSAID intolerance 13% Gastroduodenal ulcer 20% GI bleed 4% CVD 53% | 2 × 200 mg/day, n = 269 | No placebo | Naproxen 2 × 500 mg/day, n = 267 | 12 | Patient's global assessment Physcian's global assessment SF-36 | Withdrawals Adverse events Serious adverse events Laboratory tests Endoscopic ulcers | 536 |
C-071 | OA/RA ≥ 3 months, requiring NSAID, FCC 1–3 No ulcer at baseline Age 57 (22–87) years Duration of disease 10 (0.3–48) years 68% female 82% Caucasian | Cardioprotective ASA permitted NSAID intolerance 7% Gastroduodenal ulcer 12% GI bleed 2% CVD 42% | 2 × 200 mg/day, n = 365 | No placebo | Diclofenac 2 × 75 mg/day, n = 387 Ibuprofen 3 × 800 mg/day, n = 345 | 12 | Patient's global assessment Physcian's global assessment SF-36 | Withdrawals Adverse events Serious adverse events Laboratory tests Endoscopic ulcers | 1,097 |
C-102 | OA/RA, requiring NSAID >3 months Age 60 (range 18–90) years 69% female 88% Caucasian | Cardioprotective ASA permitted NSAID intolerance 9% Gastroduodenal ulcer 8% GI bleed 2% CVD 40% | 2 × 400 mg/day, n = 3,987 | No placebo | Ibuprofen 3 × 800 mg/day, n = 1,985 Diclofenac 2 × 75 mg/day, n = 1,996 | 52 | Patient's global assessment Patient's assessment of arthritis pain SF-36 SODA | Withdrawals Adverse events Serious adverse events Laboratory tests CSUGIEs | 7,968 |
C-105 | OA/RA (documented clinical diagnosis for ≥ 3 months), requiring NSAID, FCC 1–3 Age 50 (range 17–78) years Duration of disease not given 84% female Asian population | Cardioprotective ASA permitted Gastroduodenal ulcer 0.5% GI bleed 0.02% CVD 1% | 2 × 100 mg/day, n = 327 | No placebo | Diclofenac 2 × 50 mg/day, n = 330 | 12 | Patient's global assessment Physcian's global assessment Patient's assessment of arthritis pain | Withdrawals Adverse events Serious adverse events Laboratory tests Endoscopic ulcers | 657 |
C-106 | OA/RA (documented clinical diagnosis), requiring NSAID, FCC 1–3 Age 55 (range 18–80) years Duration of disease not given 17% female ≥ 99% Asian | Cardioprotective ASA permitted Gastroduodenal ulcer 9% GI bleed 3% CVD 10% | 2 × 100 mg/day, n = 63 | No placebo | Diclofenac 2 × 50 mg/day, n = 61 | 12 | Patient's global assessment Physcian's global assessment Patient's assessment of arthritis pain | Withdrawals Adverse events Serious adverse events Laboratory tests Endoscopic ulcers | 124 |
C-107 | OA/RA (documented clinical diagnosis ≥ 3 months) requiring NSAID, FCC 1–3 Age 53 (range 24–88) years Duration OA 4 (0.5–13) years, RA 6 (0.5–19) years 83% female ≥ 99% Asian | Cardioprotective ASA permitted Gastroduodenal ulcer 10% GI bleed 3% CVD 14% | 2 × 100 mg/day, n = 44 | No placebo | Diclofenac 2 × 50 mg/day, n = 44 | 12 | Patient's global assessment Physcian's global assessment Patient's assessment of arthritis pain | Withdrawals Adverse events Serious adverse events Laboratory tests Endoscopic ulcers | 88 |
C-849 (Pooled 105, 106, 107) | OA/RA | 2 × 100 mg/day, n = 434 | No placebo | Diclofenac 2 × 50 mg/day, n = 435 | 12 | Endoscopic ulcers (pooled 105, 106, 107) | 880 |
Trial inclusion and exclusion criteria
Trial methods
Information collected on adverse events
Meta-analysis
Outcomes chosen for the meta-analysis
Trial quality and validity
Analysis
Results
Trials
Patients and adverse events
Discontinuation
Number of | Incidence of events (%) | |||||||
---|---|---|---|---|---|---|---|---|
Outcome and comparisons | Celecoxib daily dose | Comparator and daily dose | Trials | Patients | Celecoxib | Comparator | Relative riska (95% CI) | NNTpb or NNHc (95% CI) |
All-cause discontinuation
| ||||||||
Celecoxib v placebo | Any | Placebo | 19 | 9,919 | 28 | 40 |
0.64 (0.61–0.68)
a
|
8.4 (7–10)
b
|
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 17 | 25 |
0.69 (0.54–0.88)
a
|
13 (8–35)
b
|
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,671 | 14 | 14 | 1.0 (0.8–1.2) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 19 | 22,616 | 23 | 23 | 0.96 (0.91–1.01) | |
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 20 | 31,711 | 31 | 34 |
0.96 (0.93–0.99)
a
|
28 (22–40)
b
|
Celecoxib (any dose) v any active | Any | Any active comparator | 26 | 35,302 | 29 | 32 |
0.95 (0.92–0.98)
a
|
36 (27–57)
b
|
Lack-of-efficacy discontinuation
| ||||||||
Celecoxib v placebo | Any | Placebo | 19 | 9,914 | 17 | 28 |
0.53 (0.49–0.57)
a
|
9.0 (8–11)
b
|
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 7.2 | 11 |
0.66 (0.45–0.97)
a
|
27 (14–390)
b
|
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,671 | 2.2 | 1.5 | 1.5 (0.84–2.6) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 19 | 22,613 | 8.0 | 6.3 |
1.1 (1.02–1.23)
a
| 58 (42–97)c |
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 20 | 31,708 | 11.3 | 10.4 | 1.02 (0.96–1.1) | |
Celecoxib (any dose) v any active | Any | Any active comparator | 26 | 35,299 | 10.6 | 9.6 | 1.0 (0.95–1.1) | |
Adverse-event discontinuation
| ||||||||
Celecoxib v placebo | Any | Placebo | 19 | 9,914 | 6.6 | 5.5 | 1.2 (0.97–1.4) | |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 4.3 | 5.4 | 0.81 (0.47–1.4) | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,662 | 6.2 | 6.8 | 0.91 (0.68–1.2) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 19 | 22,613 | 8.5 | 9.9 |
0.84 (0.77–0.92)
a
|
74 (47–180)
b
|
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 20 | 31,708 | 11.4 | 14.6 |
0.86 (0.81–0.91)
a
|
31 (25–41)
b
|
Celecoxib (any dose) v any active | Any | Any active comparator | 26 | 35,299 | 10.9 | 13.5 |
0.87 (0.82–0.92)
a
|
38 (30–51)
b
|
Gastrointestinal-adverse-event discontinuation
| ||||||||
Celecoxib v placebo | Any | Placebo | 11 | 5,933 | 2.5 | 2.0 | 1.2 (0.8–1.7) | |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 726 | 1.6 | 2.6 | 0.6 (0.2–1.6) | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,671 | 2.2 | 2.9 | 0.7 (0.5–1.2) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 11 | 18,639 | 4.8 | 6.5 |
0.7 (0.6–0.8)
a
|
58 (42–98)
b
|
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 12 | 27,299 | 6.4 | 9.6 |
0.75 (0.7–0.8)
a
|
31 (26–40)
b
|
Celecoxib (any dose) v any active | Any | Any active comparator | 18 | 30,560 | 6 | 8.7 |
0.75 (0.7–0.8)
a
|
37 (30–48)
b
|
Lack-of-efficacy discontinuations | Adverse-event discontinuations | |||||||
---|---|---|---|---|---|---|---|---|
Duration (weeks) | Treatment | Dose (mg/day) | Number of events | Total number | Discontinuations, % (95% CI) | Number of events | Total number | Discontinuations, % (95% CI) |
2–6 | Placebo | 339 | 1,925 | 17.6 (15.8–19.4) | 97 | 1,925 | 5.0 (4.0–6.0) | |
Celecoxib | <100 | 42 | 253 | 16.6 (12.1–21.1) | 8 | 253 | 3.2 (1.0–5.4) | |
Celecoxib | 100 | No data | No data | |||||
Celecoxib | 200 | 203 | 4,190 | 4.8 (4.2–5.4) | 223 | 4,190 | 5.3 (4.7–5.9) | |
Celecoxib | 400 | 12 | 155 | 7.7 (3.6–11.8) | 5 | 155 | 3.2 (0.5–5.9) | |
Celecoxib | 800 | 15 | 180 | 8.3 (4.2–12.4) | 14 | 180 | 7.8 (3.9–11.7) | |
Paracetamol | 4,000 | 55 | 502 | 11.0 (8.3–13.7) | 27 | 502 | 5.4 (3.4–7.4) | |
Rofecoxib | 25 | 19 | 1,191 | 1.6 (0.8–2.4) | 77 | 1,191 | 6.5 (5.1–7.9) | |
Naproxen | 1,000 | 5 | 395 | 1.3 (0.1–2.5) | 31 | 395 | 7.8 (5.3–10.3) | |
Diclofenac | 100/150 | 13 | 540 | 2.4 (1.0–3.8) | 51 | 540 | 9.4 (6.9–11.9) | |
12 | Placebo | 521 | 1,135 | 45.9 (43.0–48.8) | 70 | 1,135 | 6.2 (4.8–7.6) | |
Celecoxib | 100 | 145 | 692 | 21 (18.1–23.9) | 52 | 692 | 7.5 (5.5–9.5) | |
Celecoxib | 200 | 571 | 6,094 | 9.4 (8.6–10.2) | 488 | 6,094 | 8.0 (7.4–8.6) | |
Celecoxib | 400 | 492 | 6,166 | 8.0 (7.4–8.6) | 590 | 6,166 | 9.6 (8.8–10.4) | |
Celecoxib | 800 | 128 | 435 | 29.4 (25.1–33.7) | 28 | 435 | 6.4 (4.0–8.8) | |
Paracetamol | 4,000 | No data | No data | |||||
Rofecoxib | 25 | 1 | 132 | 0.8 (0.0–2.4) | 13 | 132 | 9.8 (4.7–14.9) | |
Naproxen | 1,000 | 374 | 2,399 | 15.6 (14.2–17.0) | 316 | 2,399 | 13.2 (11.8–14.6) | |
Diclofenac | 100/150 | 120 | 4,311 | 2.8 (2.2–3.4) | 338 | 4,311 | 7.8 (7.0–8.6) | |
Ibuprofen | 2,400 | 14 | 345 | 4.1 (1.9–6.3) | 37 | 345 | 10.7 (7.4–14) | |
24+ | Placebo | No data | No data | |||||
Celecoxib | 100 | No data | No data | |||||
Celecoxib | 200 | No data | No data | |||||
Celecoxib | 400 | 26 | 326 | 8.0 (5.1–10.9) | 34 | 326 | 10.4 (7.1–13.7) | |
Celecoxib | 800 | 691 | 3,987 | 17.3 (16.1–18.5) | 892 | 3,987 | 22.4 (21–23.8) | |
Paracetamol | 4,000 | No data | No data | |||||
Rofecoxib | 25 | No data | No data | |||||
Naproxen | 1,000 | No data | No data | |||||
Diclofenac | 100/150 | 331 | 2,325 | 14.2 (12.8–15.6) | 593 | 2,325 | 25.5 (23.7–27.3) | |
Ibuprofen | 2,400 | 456 | 1,985 | 23.0 (21.2–24.8) | 456 | 1,985 | 23.0 (21.2–24.8) |
Any adverse event
Number of | Incidence of events (%) | |||||||
---|---|---|---|---|---|---|---|---|
Outcome and comparisons | Celecoxib daily dose | Comparator and daily dose | Trials | Patients | Celecoxib | Comparator | Relative riska (95% CI) | NNTpb or NNHc (95% CI) |
Patient with any adverse event
| ||||||||
Celecoxib v placebo | Any | Placebo | 19 | 9,919 | 55 | 48 |
1.08 (1.04–1.13)
a
| 15 (11–21)c |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 32 | 32 | 1.0 (0.84–1.2) | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 3 | 769 | 48 | 49 | 0.97 (0.84–1.1) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 19 | 22,615 | 45 | 50 |
0.92 (0.89–0.95)
a
|
18 (14–23)
b
|
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 20 | 31,711 | 53 | 60 |
0.96 (0.94–0.98)
a
|
15 (13–18)
b
|
Celecoxib (any dose) v any active | Any | Any active comparator | 24 | 33,400 | 53 | 59 |
0.96 (0.94–0.98)
a
|
17 (14–21)
b
|
Patient with any treatment-related adverse event
| ||||||||
Celecoxib v placebo | Any | Placebo | 19 | 9,919 | 9.5 | 8.1 |
1.22 (1.06–1.40)
a
| 71 (39–450)c |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 3 | 1,056 | 9.0 | 8.8 | 1.04 (0.71–1.5) | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 4 | 1,579 | 6.6 | 9.0 | 0.74 (0.53–1.04) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 19 | 22,615 | 13.0 | 17.3 |
0.77 (0.72–0.82)
a
|
24 (19–31)
b
|
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 19 | 23,743 | 12.7 | 17.3 |
0.77 (0.72–0.82)
a
|
22 (18–27)
b
|
Celecoxib (any dose) v any active | Any | Any active comparator | 24 | 26,242 | 12.3 | 16.2 |
0.78 (0.73–0.83)
a
|
26 (21–33)
b
|
Patient with any serious adverse event
| ||||||||
Celecoxib v placebo | Any | Placebo | 19 | 9,919 | 1.0 | 1.4 |
0.67 (0.46–0.98)
a
|
280 (120–790)
b
|
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 0.5 | 0.6 | 0.76 (0.14–4.1) | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,671 | 2.3 | 2.1 | 1.1 (0.68–1.9) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 19 | 22,612 | 2.5 | 2.6 | 0.91 (0.77–1.08) | |
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 20 | 31,708 | 3.3 | 3.6 | 1.02 (0.91–1.15) | |
Celecoxib (any dose) v any active | Any | Any active comparator | 26 | 35,299 | 3.2 | 3.4 | 1.02 (0.91–1.15) | |
Patient with any gastrointestinal adverse event
| ||||||||
Celecoxib v placebo | Any | Placebo | 17 | 9,512 | 26.0 | 19.0 |
1.2 (1.1–1.4)
a
| 14 (12–19)c |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 12.0 | 11.0 | 1.1 (0.8–1.6) | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,671 | 16.0 | 18.0 | 0.87 (0.74–1.03) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 18 | 30,043 | 26.0 | 34.0 |
0.84 (0.81–0.87)
a
|
12 (10–13)
b
|
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 18 | 31,171 | 26.0 | 34.0 |
0.84 (0.81–0.87)
a
|
12 (10–13)
b
|
Celecoxib (any dose) v any active | Any | Any active comparator | 24 | 34,762 | 26.0 | 32.0 |
0.85 (0.82–0.88)
a
|
14 (12–16)
b
|
Treatment-related adverse events
Serious adverse events
Any gastrointestinal adverse event
Gastrointestinal tolerability
Nausea
Number of | Incidence of events (%) | |||||||
---|---|---|---|---|---|---|---|---|
Outcome and comparisons | Celecoxib daily dose | Comparator and daily dose | Trials | Patients | Celecoxib | Comparator | Relative riska (95% CI) | NNTpb or NNHc (95% CI) |
Gastrointestinal tolerability
| ||||||||
Celecoxib v placebo | Any | Placebo | 19 | 9,919 | 5.3 | 4.6 | 1.0 (0.82–1.2) | |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 2.0 | 2.0 | 1.0 (0.43–2.4) | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,671 | 3.2 | 4.4 | 0.72 (0.49–1.06) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 19 | 22,615 | 5.4 | 8.9 |
0.62 (0.56–0.68)
|
28 (24–36)
b
|
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 19 | 23,743 | 5.5 | 8.9 |
0.61 (0.55–0.67)
|
29 (24–36)
b
|
Celecoxib (any dose) v any active | Any | Any active comparator | 25 | 27,334 | 5.2 | 8.0 |
0.63 (0.57–0.69)
|
35 (29–45)
b
|
Nausea
| ||||||||
Celecoxib v placebo | Any | Placebo | 17 | 9,510 | 2.7 | 3.4 |
0.76 (0.60–0.97)
|
155 (71–840)
b
|
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 2.9 | 1.8 | 1.6 (0.73–3.7) | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 4 | 1,579 | 1.8 | 2.8 | 0.62 (0.32–1.2) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 17 | 22,072 | 2.7 | 3.3 | 0.87 (0.74–1.02) | |
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 18 | 31,168 | 3.8 | 5.6 |
0.80 (0.72–0.89)
|
56 (44–77)
b
|
Celecoxib (any dose) v any active | Any | Any active comparator | 23 | 33,667 | 3.7 | 5.3 |
0.81 (0.73–0.90)
|
63 (49–88)
b
|
Vomiting
| ||||||||
Celecoxib v placebo | Any | Placebo | 15 | 9,030 | 1.1 | 0.7 | 1.4 (0.86–2.4) | |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 0.7 | 1.0 | 0.73 (0.19–2.7) | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 3 | 769 | 1.0 | 0.8 | 1.3 (0.29-5.7) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 16 | 21,825 | 0.8 | 1.4 |
0.64 (0.49–0.83)
|
173 (115–350)
b
|
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 17 | 30,921 | 1.2 | 1.9 |
0.75 (0.62–0.90)
|
144 (100–250)
b
|
Celecoxib (any dose) v any active | Any | Any active comparator | 21 | 32,610 | 1.2 | 1.9 |
0.76 (0.64–0.91)
|
156 (110–280)
b
|
Vomiting
Abdominal pain
Number of | Incidence of events (%) | |||||||
---|---|---|---|---|---|---|---|---|
Outcome/ comparisons | Celecoxib daily dose | Comparator and daily dose | Trials | Patients | Celecoxib | Comparator | Relative riska (95% CI) | NNTpb or NNHc (95% CI) |
Abdominal pain
| ||||||||
Celecoxib v placebo | Any | Placebo | 19 | 9,919 | 3.6 | 2.9 | 1.2 (0.92–1.5) | |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 0.9 | 2.0 | 0.45 (0.15–1.3) | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,671 | 2.7 | 4.2 |
0.64 (0.42–0.97)
a
|
67 (35–920)
b
|
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 19 | 22,615 | 5.3 | 7.8 |
0.75 (0.68–0.83)
a
|
41 (32–57)
b
|
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 20 | 31,711 | 6.6 | 10.0 |
0.76 (0.70–0.82)
a
|
29 (25–36)
b
|
Celecoxib (any dose) v any active | Any | Any active comparator | 26 | 35,302 | 6.2 | 9.2 |
0.75 (0.70–0.81)
a
|
33 (28–41)
b
|
Dyspepsia
| ||||||||
Celecoxib v placebo | Any | Placebo | 19 | 9,919 | 6.9 | 4.8 |
1.30 (1.08–1.6)
a
| 46 (32–84)c |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 2.9 | 2.2 | 1.34 (0.63–2.9) | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,671 | 4.4 | 4.9 | 0.89 (0.63–1.3) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 19 | 22,615 | 5.7 | 7.3 |
0.79 (0.71–0.88)
a
|
61 (43–100)
b
|
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 20 | 31,711 | 8.1 | 10.7 |
0.84 (0.78–0.90)
a
|
39 (31–52)
b
|
Celecoxib (any dose) v any active | Any | Any active comparator | 26 | 35,302 | 7.8 | 9.9 |
0.85 (0.79–0.91)
a
|
48 (37–68)
b
|
Diarrhoea
| ||||||||
Celecoxib v placebo | Any | Placebo | 17 | 9,510 | 5.1 | 3.5 |
1.45 (1.16–1.82)
a
| 53 (37–97)c |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 2.2 | 4.6 |
0.48 (0.24–0.95)
a
|
41 (22–450)
b
|
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,671 | 4.1 | 4.4 | 0.93 (0.65–1.3) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 17 | 22,071 | 4.3 | 4.9 | 0.96 (0.85–1.1) | |
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 18 | 31,167 | 5.8 | 6.9 | 0.96 (0.88–1.1) | |
Celecoxib (any dose) v any active | Any | Any active comparator | 24 | 34,758 | 5.6 | 6.6 | 0.95 (0.87–1.03) | |
Clinical ulcers and bleeds
| ||||||||
Celecoxib v placebo | Any | Placebo | 16 | 9,321 | 0.03 | 0.05 | 3 events | |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 0.0 | 0.0 | 0 events | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 3 | 897 | 0.3 | 0.0 | 1 event | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 17 | 22,075 | 0.2 | 0.6 |
0.35 (0.22–0.56)
a
|
250 (170–450)
b
|
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 18 | 31,171 | 0.4 | 0.9 |
0.61 (0.46–0.81)
a
|
200 (140–320)
b
|
Celecoxib (any dose) v any active | Any | Any active comparator | 22 | 32,508 | 0.4 | 0.8 |
0.61 (0.46–0.81)
a
|
210 (150–350)
b
|
Dyspepsia
Diarrhoea
Clinical ulcers and bleeds
Myocardial infarction
Number of | Incidence of events (%) | |||||||
---|---|---|---|---|---|---|---|---|
Outcome/ comparisons | Celecoxib daily dose | Comparator and daily dose | Trials | Patients | Celecoxib | Comparator | Relative riska (95% CI) | NNTpb or NNHc (95% CI) |
Myocardial infarction
| ||||||||
Celecoxib v placebo | Any | Placebo | 16 | 9,315 | 0.12 | 0.07 | 10 events | |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 0.00 | 0.00 | 0 events | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,667 | 0.00 | 0.08 | 1 event | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 16 | 21,818 | 0.15 | 0.04 | 1.9 (0.87–4.1) | 23 events |
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 17 | 30,220 | 0.22 | 0.14 | 1.6 (0.93–2.6) | 56 events |
Celecoxib (any dose) v any active | Any | Any active comparator | 23 | 34,174 | 0.19 | 0.13 | 1.4 (0.87–2.3) | 57 events |
Celecoxib (any dose) v any comparator | Any | Any comparator | 30 | 38,499 | 0.18 | 0.12 | 1.4 (0.88–2.2) | 59 events |
Celecoxib (any dose) v noncoxib comparator | Any | Any noncoxib comparator | 28 | 36,316 | 0.19 | 0.12 | 1.4 (0.88–2.2) | 57 events |
Cardiac failure
| ||||||||
Celecoxib v placebo | Any | Placebo | 16 | 9,834 | 0.06 | 0.03 | 5 events | |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 0.00 | 0.00 | 0 events | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,671 | 0.15 | 0.60 | 10 events | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 15 | 21,859 | 0.06 | 0.15 | 0.54 (0.29–1.02) | 21 events |
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 17 | 30,917 | 0.11 | 0.20 | 0.70 (0.43–1.1) | 45 events |
Celecoxib (any dose) v any active | Any | Any active comparator | 23 | 34,512 | 0.11 | 0.23 | 0.64 (0.41–1.0) | 55 events |
Raised creatinine (above 1.3 × upper limit of normal)
| ||||||||
Celecoxib v placebo | Any | Placebo | 5 | 2,776 | 1.3 | 0.7 | 1.65 (0.69–4.0) | |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | ||||||
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | ||||||
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 9 | 15,319 | 0.3 | 0.5 | 0.78 (0.46–1.3) | |
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | ||||||
Celecoxib (any dose) v any active | Any | Any active comparator | 10 | 15,657 | 0.3 | 0.5 | 0.79 (0.47–1.3) | |
Hypertension and aggravated hypertension
| ||||||||
Celecoxib v placebo | Any | Placebo | 16 | 9,321 | 1.0 | 0.6 | 1.4 (0.85–2.4) | |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 0.2 | 0.6 | 4 events | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,671 | 3.5 | 4.6 | 0.75 (0.52–1.1) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 16 | 22,518 | 1.3 | 1.4 | 0.92 (0.73–1.2) | |
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 17 | 30,921 | 1.6 | 1.6 | 1.1 (0.90–1.3) | |
Celecoxib (any dose) v any active | Any | Any active comparator | 23 | 34,512 | 1.7 | 1.8 | 1.0 (0.86–1.2) | |
Oedema at any site
| ||||||||
Celecoxib v placebo | Any | Placebo | 16 | 9,321 | 2.6 | 1.4 |
1.9 (1.4–2.7)
|
79 (54–145)
c
|
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 2.3 | 1.8 | 1.3 (0.56–3.0) | |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,671 | 18.0 | 25.0 |
0.72 (0.62–0.83)
|
14 (10–25)
b
|
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 16 | 21,825 | 2.4 | 2.5 | 0.98 (0.82–1.2) | |
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 17 | 30,921 | 2.9 | 3.5 | 0.92 (0.81–1.05) | |
Celecoxib (any dose) v any active | Any | Any active comparator | 23 | 34,512 | 3.8 | 5.4 |
0.84 (0.76–0.92)
|
62 (48–87)
b
|
Cardiac failure
Raised creatinine
Hypertension and aggravated hypertension
Oedema at any site
Haemoglobin fall of 20 g/L or more
Number of | Incidence of events (%) | |||||||
---|---|---|---|---|---|---|---|---|
Outcome/ comparisons | Celecoxib daily dose | Comparator and daily dose | Trials | Patients | Celecoxib | Comparator | Relative riska (95% CI) | NNTpb or NNHc (95% CI) |
Haemoglobin fall of 20 g/L or more
| ||||||||
Celecoxib v placebo | Any | Placebo | 5 | 3,577 | 0.8 | 0.5 | 1.5 (0.56–4.0) | |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | ||||||
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | ||||||
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 10 | 15,746 | 1.1 | 2.2 |
0.71 (0.55–0.91)
a
|
92 (66–150)
b
|
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 10 | 16,180 | 1.1 | 2.2 |
0.72 (0.56–0.92)
a
|
93 (67–150)
b
|
Celecoxib (any dose) v any active | Any | Any active comparator | 11 | 16,990 | 1.1 | 2.1 |
0.72 (0.56–0.92)
a
|
100 (71–170)
b
|
Haematocrit fall of 5% or more
| ||||||||
Celecoxib v placebo | Any | Placebo | 9 | 6,442 | 8.1 | 6.5 | 1.20 (0.98–1.5) | |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | ||||||
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 2 | 962 | 12.6 | 17.1 | 0.74 (0.54–1.01) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 12 | 6,910 | 9.9 | 15.4 |
0.77 (0.68–0.88)
a
|
18 (14–25)
b
|
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 12 | 8,038 | 9.9 | 15.4 |
0.78 (0.69–0.89)
a
|
18 (14–25)
b
|
Celecoxib (any dose) v any active | Any | Any active comparator | 14 | 8,970 | 10.1 | 15.6 |
0.78 (0.69–0.88)
a
|
18 (14–25)
b
|
Haematocrit fall of 5% or more
Endoscopically detected ulcers
Number of | Incidence of events (%) | |||||||
---|---|---|---|---|---|---|---|---|
Outcome/ comparisons | Celecoxib daily dose | Comparator and daily dose | Trials | Patients | Celecoxib | Comparator | Relative riska (95% CI) | NNTpb or NNHc (95% CI) |
Analysis irrespective of aspirin use
| ||||||||
Celecoxib v placebo | Any | Placebo | 2 | 1,737 | 3.9 | 2.2 | 1.8 (0.89–3.6) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 6 | 4,135 | 4.6 | 16.3 |
0.30 (0.24–0.37)
a
|
8.6 (7.4–10)
b
|
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 6 | 4,565 | 4.5 | 16.3 |
0.29 (0.24–0.36)
a
|
8.4 (7.3–10)
b
|
Analysis without aspirin use
| ||||||||
Celecoxib v placebo | Any | Placebo | 2 | 1,537 | 3.3 | 1.9 | 1.8 (0.79–3.9) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 5 | 3,053 | 4.5 | 17.6 |
0.28 (0.22–0.36)
a
|
7.6 (6.5–9.1)
b
|
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 5 | 3,440 | 4.2 | 17.6 |
0.28 (0.22–0.36)
a
|
7.5 (6.4–8.9)
b
|
Analysis with aspirin use
| ||||||||
Celecoxib v placebo | Any | Placebo | 2 | 200 | 7.9 | 4.1 | 1.7 (0.45–6.3) | |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 5 | 344 | 10.0 | 23.8 |
0.47 (0.27–0.83)
a
|
7.3 (4.6–17)
b
|
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 5 | 387 | 9.9 | 23.8 |
0.48 (0.28–0.83)
a
|
7.2 (4.7–16)
b
|